PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2023; 83(03): 289-298
DOI: 10.1055/a-2018-9053
GebFra Science
Review

Update Mammakarzinom 2022 Teil 5 – Brustkrebs in frühen Krankheitsstadien

Artikel in mehreren Sprachen: English | deutsch
Tanja N. Fehm
1   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
,
Manfred Welslau
2   Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Volkmar Müller
3   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Diana Lüftner
4   Immanuel Hospital Märkische Schweiz, Buckow; Medical University of Brandenburg Theodor-Fontane, Brandenburg, Germany
,
Florian Schütz
5   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
,
Peter A. Fasching
6   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Wolfgang Janni
7   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Christoph Thomssen
8   Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
,
Isabell Witzel
3   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Milena Beierlein
6   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Erik Belleville
9   ClinSol GmbH & Co. KG, Würzburg, Germany
,
Michael Untch
10   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
,
Marc Thill
11   Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany
,
Hans Tesch
12   Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
,
Nina Ditsch
13   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
,
Michael P. Lux
14   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
,
Bahriye Aktas
15   Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
,
Maggie Banys-Paluchowski
16   Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
,
Cornelia Kolberg-Liedtke
17   Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany
,
Andreas D. Hartkopf
7   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Achim Wöckel
18   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Hans-Christian Kolberg
19   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Nadia Harbeck
20   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
,
Elmar Stickeler
21   Department of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Die Behandlung von Patientinnen mit Mammakarzinom in frühen Krankheitsstadien hat sich in den letzten Jahren durch die Einführung von Pembrolizumab, Olaparib und Abemaciclib verändert. Diese und weitere Substanzen dieser Wirkstoffklassen werden derzeit in verschiedenen Indikationen getestet. Diese Übersichtsarbeit fasst die neuesten Ergebnisse zusammen, die entweder auf den großen Kongressen wie dem ESMO 2022 oder kürzlich in internationalen Fachzeitschriften veröffentlicht worden sind. Es wird berichtet von neu entdeckten Brustkrebsgenen, Atezolizumab in der Neoadjuvanz bei HER2-positiven Patientinnen, Langzeitdaten aus der Aphinity-Studie und vom Effekt von Lokalanästhetika, die präoperativ peritumoral appliziert wurden, auf die Prognose. Ebenso werden solide Daten zum dynamischen Ki-67 aus den ADAPT-Studien vorgestellt.

Schlüsselwörter

Brustkrebs - Chirurgie - Chemotherapie - Therapiestandard


Publikationsverlauf

Eingereicht: 27. November 2022

Angenommen: 27. Dezember 2022

Artikel online veröffentlicht:
09. März 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Jia G, Ping J, Shu X. et al. Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. Am J Hum Genet 2022; DOI: 10.1016/j.ajhg.2022.10.011.
    CrossrefPubMedGoogle Scholar
  • 2 Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines 2019; 4: 7 DOI: 10.1038/s41541-019-0103-y.
    CrossrefPubMedGoogle Scholar
  • 3 Antonarelli G, Corti C, Tarantino P. et al. Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Ann Oncol 2021; 32: 1537-1551 DOI: 10.1016/j.annonc.2021.08.2153.
    CrossrefPubMedGoogle Scholar
  • 4 Corti C, Giachetti P, Eggermont AMM. et al. Therapeutic vaccines for breast cancer: Has the time finally come?. Eur J Cancer 2022; 160: 150-174 DOI: 10.1016/j.ejca.2021.10.027.
    CrossrefPubMedGoogle Scholar
  • 5 Hashimoto S, Noguchi E, Bando H. et al. Neoantigen prediction in human breast cancer using RNA sequencing data. Cancer Sci 2021; 112: 465-475 DOI: 10.1111/cas.14720.
    CrossrefPubMedGoogle Scholar
  • 6 Li W, Amei A, Bui F. et al. Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival. Cancers (Basel) 2021; DOI: 10.3390/cancers13122879.
    CrossrefPubMedGoogle Scholar
  • 7 Reimann H, Nguyen A, Sanborn JZ. et al. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. J Immunother Cancer 2021; DOI: 10.1136/jitc-2021-002605.
    CrossrefPubMedGoogle Scholar
  • 8 Denkert C, von Minckwitz G, Darb-Esfahani S. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40-50 DOI: 10.1016/S1470-2045(17)30904-X.
    CrossrefPubMedGoogle Scholar
  • 9 Ingold Heppner B, Untch M, Denkert C. et al. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clin Cancer Res 2016; 22: 5747-5754 DOI: 10.1158/1078-0432.CCR-15-2338.
    CrossrefPubMedGoogle Scholar
  • 10 Wurfel F, Erber R, Huebner H. et al. TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients – First Results on the Influence of Tumor-Infiltrating Lymphocytes. Breast Care (Basel) 2018; 13: 8-14 DOI: 10.1159/000486949.
    CrossrefPubMedGoogle Scholar
  • 11 Knutson KL, Block MS, Norton N. et al. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. Clin Cancer Res 2020; 26: 1045-1053 DOI: 10.1158/1078-0432.CCR-19-2123.
    CrossrefPubMedGoogle Scholar
  • 12 Disis ML, Guthrie KA, Liu Y. et al. Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol 2022; DOI: 10.1001/jamaoncol.2022.5143.
    CrossrefPubMedGoogle Scholar
  • 13 Badwe RA, Parmar V, Nair NS. et al. Effect of peri-tumoral infiltration of local anaesthetic prior to surgery on survival in early breast cancer. Ann Oncol 2022; 33 (Suppl. 07) S55-S84 DOI: 10.1016/annonc/annonc1089.
    CrossrefPubMedGoogle Scholar
  • 14 Zhang Y, Jing Y, Pan R. et al. Mechanisms of Cancer Inhibition by Local Anesthetics. Front Pharmacol 2021; 12: 770694 DOI: 10.3389/fphar.2021.770694.
    CrossrefPubMedGoogle Scholar
  • 15 Schmid P, Cortes J, Dent R. et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022; DOI: 10.1056/NEJMoa2112651.
    CrossrefPubMedGoogle Scholar
  • 16 Schmid P, Cortes J, Pusztai L. et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020; 382: 810-821 DOI: 10.1056/NEJMoa1910549.
    CrossrefPubMedGoogle Scholar
  • 17 Huober J, Barrios CH, Niikura N. et al. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. J Clin Oncol 2022; 40: 2946-2956 DOI: 10.1200/JCO.21.02772.
    CrossrefPubMedGoogle Scholar
  • 18 Cortes J, Rugo HS, Cescon DW. et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 2022; 387: 217-226 DOI: 10.1056/NEJMoa2202809.
    CrossrefPubMedGoogle Scholar
  • 19 Fasching PA, Hartkopf AD, Gass P. et al. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Res Treat 2019; 173: 319-328 DOI: 10.1007/s10549-018-5008-3.
    CrossrefPubMedGoogle Scholar
  • 20 Gianni L, Pienkowski T, Im YH. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32 DOI: 10.1016/S1470-2045(11)70336-9.
    CrossrefPubMedGoogle Scholar
  • 21 Gianni L, Pienkowski T, Im YH. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016; 17: 791-800 DOI: 10.1016/S1470-2045(16)00163-7.
    CrossrefPubMedGoogle Scholar
  • 22 Loibl S, Jassem J, Sonnenblick A. et al. Updated Results of Aphinity at 8.4 years median follow up. ESMO Virtual Plenary 2022; July 14, 2022.
    PubMedGoogle Scholar
  • 23 Ditsch N, Wöcke A, Untch M. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Breast Care 2022; DOI: 10.1159/000524879.
    CrossrefPubMedGoogle Scholar
  • 24 Tjan-Heijnen VCG, Lammers SWM, Geurts SME. et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial. Ann Oncol 2022; 33 (Suppl. 07) S55-S84 DOI: 10.1016/annonc/annonc1089.
    CrossrefPubMedGoogle Scholar
  • 25 Harbeck N, Rastogi P, Martin M. et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32: 1571-1581 DOI: 10.1016/j.annonc.2021.09.015.
    Google Scholar
  • 26 Nelson DR, Brown J, Morikawa A. et al. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLoS One 2022; 17: e0264637 DOI: 10.1371/journal.pone.0264637.
    CrossrefPubMedGoogle Scholar
  • 27 Gnant M, Dueck AC, Frantal S. et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol 2022; 40: 282-293 DOI: 10.1200/JCO.21.02554.
    CrossrefPubMedGoogle Scholar
  • 28 Mayer EL, Dueck AC, Martin M. et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2021; 22: 212-222 DOI: 10.1016/S1470-2045(20)30642-2.
    CrossrefPubMedGoogle Scholar
  • 29 Loibl S, Marme F, Martin M. et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol 2021; 39: 1518-1530 DOI: 10.1200/JCO.20.03639.
    CrossrefPubMedGoogle Scholar
  • 30 clinicaltrials.gov. NCT03701334. A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE). NIH US National Library of Medicine 2018. Zugriff am 07. November 2020 unter: https://clinicaltrials.gov/ct2/show/NCT03701334
    PubMedGoogle Scholar
  • 31 Slamon DJ, Fasching PA, Patel R. et al. NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC). J Clin Oncol 2019; 37: TPS597-TPS597 DOI: 10.1200/JCO.2019.37.15_suppl.TPS597.
    Google Scholar
  • 32 Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440-1452 DOI: 10.1016/S0140-6736(18)33137-4.
    CrossrefPubMedGoogle Scholar
  • 33 Mastro LD, Poggio F, Blondeaux E. et al. Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM). Ann Oncol 2022; 33 (Suppl. 07) S55-S84 DOI: 10.1016/annonc/annonc1089.
    CrossrefPubMedGoogle Scholar
  • 34 Del Mastro L, De Placido S, Bruzzi P. et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 2015; 385: 1863-1872 DOI: 10.1016/S0140-6736(14)62048-1.
    CrossrefPubMedGoogle Scholar
  • 35 Gluz O, Nitz UA, Christgen M. et al. Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials. Ann Oncol 2022; 33 (Suppl. 07) S808-S869 DOI: 10.1016/annonc/annonc1089.
    CrossrefPubMedGoogle Scholar
  • 36 Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 2022; 23: 382-392 DOI: 10.1016/S1470-2045(21)00758-0.
    CrossrefPubMedGoogle Scholar
  • 37 Pivot X, Pegram M, Cortes J. et al. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer 2019; 120: 1-9 DOI: 10.1016/j.ejca.2019.07.015.
    CrossrefPubMedGoogle Scholar
  • 38 Norton N, Olson RM, Pegram M. et al. Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunol Res 2014; 2: 962-969 DOI: 10.1158/2326-6066.CIR-14-0059.
    CrossrefPubMedGoogle Scholar
  • 39 Musolino A, Naldi N, Bortesi B. et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796 DOI: 10.1200/JCO.2007.14.8957.
    CrossrefPubMedGoogle Scholar
  • 40 Hurvitz SA, Betting DJ, Stern HM. et al. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012; 18: 3478-3486 DOI: 10.1158/1078-0432.CCR-11-2294.
    CrossrefPubMedGoogle Scholar
  • 41 Gavin PG, Song N, Kim SR. et al. Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. JAMA Oncol 2017; 3: 335-341 DOI: 10.1001/jamaoncol.2016.4884.
    CrossrefPubMedGoogle Scholar
  • 42 Rugo HS, Im SA, Cardoso F. et al. Efficacy of Margetuximab vs. Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; DOI: 10.1001/jamaoncol.2020.7932.
    CrossrefPubMedGoogle Scholar
  • 43 Rugo HS, Im SA, Cardoso F. et al. SOPHIA Study Group. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. J Clin Oncol 2023; 41: 198-205 DOI: 10.1200/JCO.21.02937.
    CrossrefPubMedGoogle Scholar
  • 44 clinicaltrials.gov. NCT05036005. Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) (NeoON). NIH US National Library of Medicine 2022; 2022. Zugriff am 01. November 2022 unter: https://clinicaltrials.gov/ct2/show/NCT05036005
    Google Scholar
  • 45 Amiah MA, Ouattara A, Okou DT. et al. Polymorphisms in Fc Gamma Receptors and Susceptibility to Malaria in an Endemic Population. Front Immunol 2020; 11: 561142 DOI: 10.3389/fimmu.2020.561142.
    CrossrefPubMedGoogle Scholar